Delivery Order SPE2DB22D3016-SPE2DB25FARL9
Award Date
3/17/25
Potential Completion Date
4/7/25
Potential Value
$61K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $48,077.16, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract is a Firm Fixed Price Delivery Order with a period of performance ending on January 28, 2025. The contract was not set aside for any specific business category. In addition to this delivery...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $24,038.58 firm fixed-price delivery order is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a pharmaceutical product. The contract has an ultimate completion date of May 6, 2025. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, designated as SPE2DX, which provides a...
This is a federal contract award issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order with a firm fixed price of $48,077.16 and a period of performance through May 14, 2025. The contract provides for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. This contract is not set-aside and was competitively awarded. AmerisourceBergen Drug Corp...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $120,192.80, is a Delivery Order under the DLA's Indefinite Delivery Contract (IDC) for pharmaceutical products and medical supplies, which is valued at $999,999,999 and runs through November 2026. The specific product being delivered under this contract is OCREVUS 300 MG/10 ML VIAL 10ML. The...
This federal contract award, valued at $72,115.74, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Firm Fixed Price Delivery Order for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a medical product. The contract has an ultimate completion date of April 14, 2025 and was awarded on March 24, 2025. There is no set-aside designation associated with this contract....
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $180,289.20 firm fixed-price delivery order is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a prescription medication. The contract has an ultimate completion date of June 4, 2025. This award is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop...
This is a federal contract award by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $76,516.65 delivery order contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. The contract has an ultimate completion date of October 3, 2022 and is a firm fixed-price agreement. This award is part of a larger $999,999,999 Indefinite Delivery Contract...
This federal contract award to AmerisourceBergen Drug Corp Corporate Office Division is a delivery order valued at $57,795.20 for the supply of OCREVUS 300 MG/10 ML VIAL 10ML. The contract is a firm fixed-price agreement with the Defense Logistics Agency (DLA), a defense agency. The contract has an ultimate completion date of September 3, 2024. AmerisourceBergen, a major pharmaceutical distributor, is the prime contractor for this award, which is not set aside for any specific business type....
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract, valued at $47,834.16, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract is a Firm Fixed Price Delivery Order with a completion date of January 8, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $72,115.74, is for the delivery of OCREVUS 300 mg/10 ml vials over a performance period ending on May 20, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a...